doi: 10.1007/978-3-030-57369-0_8.
- PMID: 33332007
- DOI: 10.1007/978-3-030-57369-0_8
Abstract
The emerging role of the endocannabinoid system (ECS) in the control of symptoms and disease progression in multiple sclerosis (MS) has been highlighted by recent studies. MS is a chronic, immune-mediated, and demyelinating disorder of the central nervous system with no cure so far. It is widely reported that cannabinoids might be used to control MS symptoms and that they also might exert neuroprotective effects and slow down disease progression. The aim of this chapter is to give an overview of the main endogenous and synthetic cannabinoids used for the symptomatic amelioration of MS and their beneficial outcomes, providing new possible perspectives for the treatment of this disease.
Keywords: Arachidonoylethanolamine (AEA) reuptake inhibitors, Cannabinoid receptors, Endocannabinoid system, Fatty acid amide hydrolase (FAAH) inhibitors, Monoacylglycerol lipase (MAGL) inhibitors, Multiple sclerosis
References
-
- Alhouayek M, Muccioli GG (2014) COX-2-derived endocannabinoid metabolites as novel inflammatory mediators trends. Pharmacol Sci 35:284–292
-
- Andrzejewski K, Barbano R, Mink J (2016) Cannabinoids in the treatment of movement disorders: a systematic review of case series and clinical trials. Basal Ganglia 6:73–181 – DOI
